ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024
SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2024 on Thursday, April 25, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
Earnings webcast details:
• Location: | http://investor.resmed.com | |
• Date: | Thursday, April 25, 2024 | |
• Time: | 1:30 p.m. PDT / 4:30 p.m. EDT | |
• International: | London, Thursday, April 25, 2024, 9:30 p.m. BST Sydney, Friday, April 26, 2024, 6:30 a.m. AEST | |
Please note, ResMed does not use outside phone lines to access the earnings call, the call is accessible via the above webcast link only.
A replay of the earnings webcast will be accessible on ResMed’s website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately three hours after the webcast and will be accessible from April 25, 2024, until May 9, 2024, at:
- U.S.: +1 877.660.6853
- International: +1 201.612.7415
- Conference ID: 13745785
About ResMed
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, COPD, and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease, and lower costs for consumers and healthcare systems in more than 140 countries. To learn more, visit ResMed.com and follow @ResMed.
For investors +1 858.836.5000 investorrelations@resmed.com | For media +1 619.510.1281 news@resmed.com |
-
After Earnings, Is Marvell Stock a Buy, a Sell, or Fairly Valued?
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Best- and Worst-Performing Stocks of May 2024
-
3 Stocks to Buy and 3 Stocks to Sell in June
-
Markets Brief: Friday’s Job Report in Focus
-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
Nvidia Raised Its Dividend — but Don’t Get Excited
-
Lululemon Earnings: On Track to Meet Expectations Despite Slowdown In Americas
-
What Is Driving Small-Cap Stock Underperformance?
-
After Earnings, Is Zscaler Stock a Buy, a Sell, or Fairly Valued?
-
ASML Fair Value Raised as Outlook Improves
-
The Best Tech Stocks to Buy
-
Undervalued by 40%, This Stock Is a Buy After Earnings
-
After Earnings, Is MongoDB Stock a Buy, a Sell, or Fairly Valued?